Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > PD-1 > PD1-R52H3

Rhesus macaque PD-1 / PDCD1 Protein, His Tag (MALS verified)

Order Now

  • Synonym
    PDCD1,PD1,CD279,SLEB2
  • Source
    Rhesus macaque PD-1, His Tag(PD1-R52H3) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # B0LAJ2-1).
    Predicted N-terminus: Leu 25
  • Molecular Characterization
    PD-1 Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 17.9 kDa. The protein migrates as 33-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
PD-1 SDS-PAGE

Rhesus macaque PD-1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS
PD-1 MALS images

The purity of Rhesus macaque PD-1, His Tag (Cat. No. PD1-R52H3) is more than 95% and the molecular weight of this protein is around 25-35 kDa verified by SEC-MALS.

Bioactivity-ELISA
 PD-1 ELISA

Immobilized Rhesus macaque PD-1, His Tag (Cat. No. PD1-R52H3) at 2 μg/mL (100 μL/well) can bind nivolumab with a linear range of 0.1-6 ng/mL (QC tested).

 PD-1 ELISA

Immobilized Biotinylated Human PD-L2, Fc,Avitag (Cat. No. PD2-H82F6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Rhesus macaque PD-1, His Tag (Cat. No. PD1-R52H3) with a linear range of 0.01-0.313 μg/mL (Routinely tested).

 PD-1 ELISA

Immobilized Biotinylated Human PD-L1, Fc,Avitag (Cat. No. PDL-H82F2) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Rhesus macaque PD-1, His Tag (Cat. No. PD1-R52H3) with a linear range of 0.078-0.625 μg/mL (Routinely tested).

  • Background
    Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $350.00

Price(USD) : $2540.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:16 Details
  • Number of Drugs in Clinical Trials:150 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message